Figure 2.
Figure 2. A hypothetical future treatment algorithm for patients with multiple myeloma. / A proposed treatment algorithm using novel agents, which is described in greater detail in the text. This algorithm includes regimens for which there is current support, such as MPT, as well as others that still require validation in a prospective fashion. / Abbreviations: BP, bendamustine and prednisone; FGFR, fibroblast growth factor receptor; ISS, International Staging System; MDT, melphalan and dexamethasone with thalidomide; MP, melphalan and prednisone; MPT, melphalan and prednisone with thalidomide; R-MP, melphalan and prednisone with lenalidomide; ThaDD, thalidomide with pegylated liposomal doxorubicin and dexamethasone; VMP, melphalan and prednisone with bortezomib

A hypothetical future treatment algorithm for patients with multiple myeloma.

A proposed treatment algorithm using novel agents, which is described in greater detail in the text. This algorithm includes regimens for which there is current support, such as MPT, as well as others that still require validation in a prospective fashion.

Abbreviations: BP, bendamustine and prednisone; FGFR, fibroblast growth factor receptor; ISS, International Staging System; MDT, melphalan and dexamethasone with thalidomide; MP, melphalan and prednisone; MPT, melphalan and prednisone with thalidomide; R-MP, melphalan and prednisone with lenalidomide; ThaDD, thalidomide with pegylated liposomal doxorubicin and dexamethasone; VMP, melphalan and prednisone with bortezomib

Close Modal

or Create an Account

Close Modal
Close Modal